- Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis — Recruiting • NCT06465810.
- Study tracking disease progression and treatment outcomes in patients with ATTR amyloidosis, including the new drug eplontersen.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected. Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR Interventions: Treatment of transthyretin (ATTR) amyloidosis in observational study setting Lead Sponsor: AstraZeneca Planned Enrollment: 1850 participants